SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Noven Pharmaceuticals (NOVN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John McCarthy who wrote (39)3/10/1999 5:58:00 PM
From: zizzerzazzer  Read Replies (1) of 66
 
Fahnestock issued an updated Research Bulletin on NOVN today. Still rate a Strong Buy. However, nothing really new in the bulletin. Still at $0.10 EPS in 1999, $0.43 in 2000 and $0.90 in 2001 (non-taxed) and 3-year target of $21. They did mention that they expect a relatively high level of Combipatch sample production throughout 1999 as RPR continues to heavily promote the product.

Note that sample products are not included in script trends.
Fahnestock projects year-end 1999 script level of 45,000 per week. NOVN receives a royalty of 30% to 35% fo RPR's sales and also profitable compensation for the manufacture of Combipatch samples (2 patches = one week). Did not say how profitable samples are.

I don't know if Fahnestock is just being ultra-conservative with its 1999 EPS estimates or if they believe the high level of sample production will restrict margins in 1999. IMHO, I believe NOVN will easily beat $0.10 EPS in 1999. Any thoughts or comments?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News